Publications by authors named "Mark Sumeray"

Claim this Profile
A
A Randomized, Double-Blind, Placebo-Controlled Pilot Trial With Open-Label Extension of Sirona, a Hydrogel for Weight Loss.
James P Byrne, Elanor C Hinton, Asif Malik Humayun, Dimitri J Pournaras, Rebecca L Elsworth, Mark Sumeray

Obesity (Silver Spring)· January 2026

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase 1 clinical trial of eneboparatide, a novel PTH receptor 1 agonist.
Michel Ovize, Soraya Allas, Michael D Culler, Stephane Milano, Taha Ouldrouis, Mark Sumeray

Endocr Connect· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
An Open-label Phase 2 Study of Eneboparatide, a Novel PTH Receptor 1 Agonist, in Hypoparathyroidism.
Istvan Takacs, Emese Mezosi, Alfonso Soto, Peter Kamenický, Lucile Figueres, Mark Sumeray

J Clin Endocrinol Metab· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Double-Blind, Placebo-Controlled, Dose-Escalating Study Evaluating the Safety and Immunogenicity of an Epitope-Specific Chemically Defined Nanoparticle RSV Vaccine.
Isabel Leroux-Roels, Jacques Bruhwyler, Lilli Stergiou, Mark Sumeray, Jasper Joye

Vaccines (Basel)· February 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of Oleogel-S10 (birch triterpenes) for epidermolysis bullosa: results from the phase III randomized double-blind phase of the EASE study.
Johannes S Kern, Eli Sprecher, Maria Florencia Fernandez, Franziska Schauer, Christine Bodemer, Mark Sumeray

Br J Dermatol· January 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Oleogel-S10 Phase 3 study "EASE" for epidermolysis bullosa: study design and rationale.
Johannes S Kern, Agnes Schwieger-Briel, Sandra Löwe, Mark Sumeray, Charles Davis

Trials· June 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetics and Pharmacodynamics of Lomitapide in Japanese Subjects.
Jorg Taubel, Mark Sumeray, Ulrike Lorch, Andre McLean

J Atheroscler Thromb· May 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluation of the effects of the weak CYP3A inhibitors atorvastatin and ethinyl estradiol/norgestimate on lomitapide pharmacokinetics in healthy subjects.
Gina Patel, Alex King, Santanu Dutta, Sarah Korb, Janet R Wade, Mark Sumeray

J Clin Pharmacol· January 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Lomitapide at supratherapeutic plasma levels does not prolong the Qtc interval--results from a TQT study with moxifloxacin and ketoconazole.
Borje Darpo, Georg Ferber, Meijian Zhou, Mark Sumeray, Philip Sager

Ann Noninvasive Electrocardiol· November 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetics, pharmacodynamics, and safety of clevidipine after prolonged continuous infusion in subjects with mild to moderate essential hypertension.
William B Smith, Thomas C Marbury, Steven F Komjathy, Mark S Sumeray, Gregory C Williams

Eur J Clin Pharmacol· October 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Reply by authors: "Technique of urethral retro-resistance pressure measurement".
Mark Slack, Patrick Culligan, Michael Tracey, Kimberly Hunsicker, Bababhai Patel, Mark Sumeray

Neurourol Urodyn· February 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Re: Subcuticular closure versus dermabond: a prospective randomized trial.
Bob Patel, Mark Sumeray

Am Surg· April 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis